Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026)
Nuvalent (NUVL) reported Cash from Financing Activities of $9.8 million for Q1 2026, up 115.5% on a YoY basis from $4.5 million in Q1 2025, and down 98.04% quarter-over-quarter from $500.3 million in Q4 2025.
Nuvalent (NUVL) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Nuvalent has reported Cash from Financing Activities for 7 years, with the latest figure at $9.8 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 115.5% year-over-year to $9.8 million; the trailing twelve-month figure through Mar 2026 stood at $520.6 million (down 8.26% YoY), and the FY2025 full-year result was $515.3 million, down 9.41% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $9.8 million, down from $500.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $550.3 million in Q3 2024, with the low at -$768000.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $98.8 million across 5 years, with a median of $4.8 million in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 107.68% — and 2024, when it jumped 35311.76%.
- Nuvalent's Cash from Financing Activities stood at $248.7 million in 2022, then jumped by 34.08% to $333.4 million in 2023, then plunged by 97.45% to $8.5 million in 2024, then surged by 5791.0% to $500.3 million in 2025, then sank by 98.04% to $9.8 million in 2026.
- The last three Cash from Financing Activities figures came in at $9.8 million (Q1 2026), $500.3 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.80 Mn |
| Mar 31, 2026 | 9.80 Mn |
| Dec 31, 2025 | 500.26 Mn |
| Dec 31, 2025 | 500.26 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Jun 30, 2025 | 5.76 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 550.27 Mn |
| Sep 30, 2024 | 550.27 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Jun 30, 2024 | 4.14 Mn |
| Mar 31, 2024 | 5.99 Mn |
| Mar 31, 2024 | 5.99 Mn |
| Dec 31, 2023 | 333.42 Mn |
| Dec 31, 2023 | 333.42 Mn |